Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973.

2.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5.

PMID:
22878899
3.

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Le DT, Lutz E, Uram JN, Sugar EA, Onners B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, Laheru DA.

J Immunother. 2013 Sep;36(7):382-9. doi: 10.1097/CJI.0b013e31829fb7a2.

4.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4.

PMID:
22326922
5.

TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.

Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L.

Oncotarget. 2015 Dec 15;6(40):43005-15. doi: 10.18632/oncotarget.5656.

6.

Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM.

J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244.

7.

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.

Wada S, Jackson CM, Yoshimura K, Yen HR, Getnet D, Harris TJ, Goldberg MV, Bruno TC, Grosso JF, Durham N, Netto GJ, Pardoll DM, Drake CG.

J Transl Med. 2013 Apr 4;11:89. doi: 10.1186/1479-5876-11-89.

8.

The evolving role of immunotherapy in prostate cancer.

Gerritsen WR.

Ann Oncol. 2012 Sep;23 Suppl 8:viii22-7. doi: 10.1093/annonc/mds259. Review.

PMID:
22918924
9.

Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.

Curran MA, Allison JP.

Cancer Res. 2009 Oct 1;69(19):7747-55. doi: 10.1158/0008-5472.CAN-08-3289.

10.

Epitopes on thyroglobulin: a study of patients with thyroid disease.

Caturegli P, Mariotti S, Kuppers RC, Burek CL, Pinchera A, Rose NR.

Autoimmunity. 1994;18(1):41-9.

PMID:
7528064
11.

Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA.

Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Erratum in: Cancer Immunol Res. 2016 May;4(5):472.

12.

Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.

Karan D, Dubey S, Van Veldhuizen P, Holzbeierlein JM, Tawfik O, Thrasher JB.

Immunotherapy. 2011 Jun;3(6):735-46. doi: 10.2217/imt.11.59.

PMID:
21668311
13.

Molecular insights into the development of T cell-based immunotherapy for prostate cancer.

Dong B, Minze LJ, Xue W, Chen W.

Expert Rev Clin Immunol. 2014 Nov;10(11):1547-57. doi: 10.1586/1744666X.2014.962515. Review.

PMID:
25259804
14.

The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo.

Silva A, Mount A, Krstevska K, Pejoski D, Hardy MP, Owczarek C, Scotney P, Maraskovsky E, Baz Morelli A.

J Immunol. 2015 Mar 1;194(5):2199-207. doi: 10.4049/jimmunol.1402228.

15.

Human monoclonal thyroglobulin autoantibodies: epitopes and immunoglobulin genes.

Latrofa F, Phillips M, Rapoport B, McLachlan SM.

J Clin Endocrinol Metab. 2004 Oct;89(10):5116-23.

PMID:
15472215
16.

Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Amedei A, Niccolai E, Prisco D.

Hum Vaccin Immunother. 2014;10(11):3354-68. doi: 10.4161/hv.34392. Review.

17.
18.

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Yuan J, Ginsberg B, Page D, Li Y, Rasalan T, Gallardo HF, Xu Y, Adams S, Bhardwaj N, Busam K, Old LJ, Allison JP, Jungbluth A, Wolchok JD.

Cancer Immunol Immunother. 2011 Aug;60(8):1137-46. doi: 10.1007/s00262-011-1011-9. Review.

19.
20.

Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy.

Liang SC, Moskalenko M, Van Roey M, Jooss K.

Clin Immunol. 2013 Aug;148(2):287-98. doi: 10.1016/j.clim.2013.05.011.

PMID:
23811319
Items per page

Supplemental Content

Support Center